Aptar Pharma's Obtains Import Licence in China
Aptar Pharma has obtained a State Food and Drug Administration (SFDA) import licence approval to deliver its preservative-free multi-dose systems to customers in China.The licence approval represents a further step in Aptar Pharma’s ongoing service development to provide large-scale production services to customers, mainly for its Ophthalmic Squeeze Dispenser (OSD) and its Advanced Preservative Free spray pump (APF).
Aptar Pharma Enlarges its Service Scope in China
In China, the pharmaceutical sector remains dynamic, outpacing growth in developed countries. The import of packaging materials for pharmaceutical products requires an “Examination and approval for packaging materials and containers in direct contact with drugs” from the SFDA before being placed on the market. Now that this import licence approval has been granted for the Ophthalmic Squeeze Dispenser (OSD) and Advanced Preservative-Free Systems (APF), pharmaceutical and biotechnology companies can directly import Aptar Pharma’s preservative-free multi-dose systems into the Chinese market. The OSD is manufactured in a class ISO 7 cleanroom at the Aptar Pharma state-of-the-art production facility in Eingeltingen, Germany.
Preservative-Free Systems are Key to Drug Manufacturers
Preservative-free systems are highly appreciated by patients who experience side effects from preservatives like benzalkonium chloride during chronic use. The APF spray pumps and the OSD systems follow a purely mechanical approach to prevent contamination via the orifice. The applied technology is referred to as “tip seal technology” and well established on other markets.
A key element of Aptar Pharma’s preservative-free technology is a spring-loaded tip seal that keeps the system closed until a defined pressure is reached during actuation and the formulation is dispensed through the orifice. When the pressure drops consequently, the tip seal immediately closes the orifice by an outward movement, which prevents any back-flow of contaminated liquids or particles.
For the venting air, Aptar Pharma uses a sterile filter to stop micro-organisms from entering. The fluid path of these systems is “metal-free”, which means the springs needed for the device operation do not come in contact with the formulation. The technology is widely established and market proven in both nasal and ophthalmic applications.
In addition, the APF spray pumps and the OSD systems are designed to be patient-friendly and easy to use to help improve patient compliance with the medical treatment. The 360° functionality of the APF spray pumps ensures convenient and safe handling; especially for pediatric use. Aptar Pharma’s OSD system is engineered for intuitive handling, smooth actuation and precise and reproducible dosage, all this with pocket sized design.
Aptar Pharma Established in China Since 1996
The import license will help meet market demand in China and further establishes Aptar Pharma’s presence in China, through its production site in Suzhou, near Shanghai. Aptar Pharma Suzhou was established in 1996 and produces pMDI metering valves and spray pumps for the Asian market. The site serves the majority of the local Chinese pharmaceutical companies, whether they are producing drug products for the domestic market or for other Asian regions.
“We are pleased to announce the import licence for the OSD technology and APF pump technology to China. We have had tremendous success marketing these technologies in other regions of the world and we are confident that our customers and consumers in China will value the benefits of our preservative free systems. As with any of our technologies, we continue to invest in ways to even further improve our devices as we adapt to our customers’ future needs and expectations”, said Matthias Birkhoff, Vice President Business Development for Aptar Pharma CHC Division.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance